Pharmacodynamic model for chemotherapy-induced anemia in rats

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 123-133

  Woo, Sukyung ^a   Krzyzanski, Wojciech ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CONTROLLED STUDY; ERYTHROCYTE CONCENTRATE; HEMOGLOBIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOCYTE COUNT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TOXICOKINETICS;

ALGORITHMS; ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CARBOPLATIN; CELL COUNT; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; HEMATOPOIESIS; HEMOGLOBINS; LEUKOCYTE COUNT; MALE; MODELS, STATISTICAL; PLATELET COUNT; RATS; STEM CELLS;

EID: 42149160079     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0582-9     Document Type: Article

References (50)

1. Henry DH (2004) The evolving role of epoetin alfa in cancer therapy. Oncologist 9:97-107
2. Cella D, Dobrez D, Glaspy J (2003) Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14:511-519
3. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz H-J, Nortier JWR (2003) Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373
4. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882
5. Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L (2004) Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 9:90-96
6. Patton J, Reeves T, Wallace J (2004) Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 9:451-458
7. Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G (2006) Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11:206-216
8. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107
9. Friberg LE, Freijs A, Sandstrom M, Karlsson MO (2000) Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734-40
10. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721
11. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K (1998) Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64:511-521
12. Krzyzanski W, Jusko WJ (2002) Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn 29:311-337
13. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409
14. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25:371-379
15. Woo S, Krzyzanski W, Jusko WJ (2006) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 319:1297-1306
16. Guo P, Li S, Gallo JM (2003) Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. J Chromatogr B 783:43-52
17. Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloro- platinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972-1979
18. Schmalbach TK, Borch RF (1989) Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine (cyclobutanedicarboxylato) platinum (II). Cancer Res 49:6629-6633
19. Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level. Oncol Rep 10:1663-1682 (Review)
20. Krzyzanski W, Ramakrishnan R, Jusko WJ (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27:467-489
21. Siddik ZH, Boxall FE, Harrap KR (1987) Haematological toxicity of carboplatin in rats. Br J Cancer 55:375-379
22. Wintrobe MM (2003) Wintrobe's clinical hematology. Lippincott Williams & Wilkins, Philadelphia
23. Laird AK (1964) Dynamics of tumor growth. Br J Cancer 13:490-502
24. D'Argenio DZ, Schumitzky A (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic system analysis software. Biomedical Simulations Resource, Los Angeles
25. Zhang Y, Andrews MC, Schyvens CG, McKenzie KU, Whitworth JA (2004) Adrenocorticotropic hormone, blood pressure, and serum erythropoietin concentrations in the rat. Am J Hypertens 17:457-461
26. Bernstein SH, Jusko WJ, Krzyzanski W, Nichol J, Wetzler M (2002) Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. J Clin Pharmacol 42:501-511
27. Desoize B, Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317-325
28. Davies MS, Berners-Price SJ, Hambley TW (2000) Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg Chem 39:5603-5613
29. van der Vijgh WJ (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242-261
30. O'Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59:19-27
31. Tanke HJ, van Vianen PH, Emiliani FM, Neuteboom I, de Vogel N, Tates AD, de Bruijn EA, van Oosterom AT (1986) Changes in erythropoiesis due to radiation or chemotherapy as studied by flow cytometric determination of peripheral blood reticulocytes. Histochemistry 84:544-548
32. Matsumoto T, Endoh K, Kamisango K, Akamatsu K, Koizumi K, Higuchi M, Imai N, Mitsui H, Kawaguchi T (1990) Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol 75:463-468
33. Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P (2004) Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. J Pharmacol Exp Ther 310:202-208
34. Eckardt K-U, Dittmer J, Neumann R, Bauer C, Kurtz A (1990) Decline of erythropoietin formation at continuous hypoxia is not due to feedback inhibition. Am J Physiol 258:F1432-F1437
35. Jelkmann W (1982) Temporal pattern of erythropoietin titers in kidney tissue during hypoxic hypoxia. Pflugers Arch 393:88-91
36. Abbrecht PH, Littell JK (1972) Plasma erythropoietin in men and mice during acclimatization to different altitudes. J Appl Physiol 32:54-58
37. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12:5481-5490
38. Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76:567-578
39. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57:412-426
40. van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23:225-234
41. Hartley C, Elliott S, Begley CG, McElroy P, Sutherland W, Khaja R, Heatherington AC, Graves T, Schultz H, Del Castillo J, Molineux G (2003) Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha. Br J Haematol 122:623-636
42. Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61:1358-1361
43. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78:752-756
44. Skomorovski K, Harpak H, Ianovski A, Vardi M, Visser TP, Hartong SC, van Vliet HH, Wagemaker G, Agur Z (2003) New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model. Br J Haematol 123:683-691
45. Stefanich EG, Carlson-Zermeno CC, McEvoy K, Reich M, Fielder PJ (2001) Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice. Cancer Chemother Pharmacol 47:70-77
46. Ron IG, Peleg L, Rienstein S, Dotan A, Ticher A, Wolfson S, Ashkenazi IE (1998) Time dependency of hematopoietic growth factor coupled to chronotoxicity of carboplatin. Cancer Chemother Pharmacol 42:135-141
47. Criswell KA, Sulkanen AP, Hochbaum AF, Bleavins MR (2000) Effects of phenylhydrazine or phlebotomy on peripheral blood, bone marrow and erythropoietin in Wistar rats. J Appl Toxicol 20:25-34
48. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA (2000) A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther 295:346-351
49. Redondo PA, Alvarez AI, Diez C, Fernandez-Rojo F, Prieto JG (1995) Physiological response to experimentally induced anemia in rats: a comparative study. Lab Anim Sci 45:578-583
50. Unami A, Nishina N, Terai T, Sato S, Tamura T, Noda K, Mine Y (1996) Effects of cisplatin on erythropoietin production in rats. J Toxicol Sci 21:157-165